Retatrutide vs Tirzepatide vs Semaglutide: Comparing the Metabolic Peptides

The incretin peptide class has evolved rapidly. In the span of a few years, metabolic peptide research has progressed from single-receptor compounds to dual-receptor and now triple-receptor agonists. Semaglutide, tirzepatide, and retatrutide represent three generations of this progression — each building on the pharmacological foundation of the last.

This article compares all three compounds across their receptor pharmacology, clinical data, and research implications.

The Core Difference: Receptor Targets

The fundamental distinction between these three peptides is how many receptors they activate:

Semaglutide is a GLP-1 single agonist. It activates one receptor — the GLP-1 receptor.

Tirzepatide is a GLP-1/GIP dual agonist. It activates two receptors — GLP-1 and GIP.

Retatrutide is a GLP-1/GIP/Glucagon triple agonist. It activates three receptors — GLP-1, GIP, and the glucagon receptor. It is the first compound of its kind to reach advanced clinical trials.

Each additional receptor target introduces new metabolic pathways into the compound's mechanism of action.

What Each Receptor Does

GLP-1 (Glucagon-Like Peptide-1) — Stimulates glucose-dependent insulin secretion, suppresses glucagon release, slows gastric emptying, and promotes satiety through hypothalamic signaling. This is the shared pathway across all three compounds.

GIP (Glucose-Dependent Insulinotropic Polypeptide) — Enhances insulin secretion and may influence fat metabolism, lipid storage, and energy expenditure. GIP receptors are expressed in the pancreas, adipose tissue, bone, and central nervous system. Tirzepatide and retatrutide both engage this receptor; semaglutide does not.

Glucagon receptor — Glucagon is traditionally associated with raising blood glucose by stimulating hepatic glucose output. However, glucagon signaling also increases energy expenditure, promotes lipid oxidation, and may reduce hepatic fat content. Retatrutide is the only one of the three that activates this receptor. The inclusion of glucagon agonism was initially counterintuitive, but research suggests that when combined with GLP-1 and GIP activity, the net metabolic effect may be beneficial rather than hyperglycemic.

Clinical Trial Comparisons

Semaglutide (STEP program): The STEP 1 trial demonstrated a mean weight reduction of approximately 14.9% from baseline over 68 weeks with semaglutide 2.4mg weekly.

Tirzepatide (SURMOUNT program): The SURMOUNT-1 trial reported mean weight reductions of up to 22.5% from baseline at the highest dose over 72 weeks.

Retatrutide (Phase 2): A 48-week Phase 2 trial reported mean weight reductions of up to 24.2% from baseline at the highest dose. Notably, this was achieved in a shorter timeframe than the tirzepatide results, and with the weight loss curve still trending downward at the study endpoint — suggesting the maximum effect had not yet been reached.

It is important to note that cross-trial comparisons have significant limitations. Trial populations, dosing schedules, inclusion criteria, and endpoint definitions differ between studies. Direct head-to-head data between all three compounds does not yet exist.

Molecular Profiles

Semaglutide: Molecular weight ~4114 g/mol, CAS 910463-68-2

Tirzepatide: Molecular weight ~4813 g/mol, CAS 2023788-19-2

Retatrutide: Molecular weight ~4814 g/mol, CAS 2381089-83-2

All three are available from Durham Peptides in 10mg lyophilized vials:

Semaglutide – 10mg Tirzepatide – 10mg Retatrutide – 10mg

Which One Do Researchers Choose?

This depends entirely on the research question:

Researchers studying established GLP-1 signaling pathways may prefer semaglutide, which has the longest research history and largest body of published clinical data.

Researchers studying the role of dual incretin signaling may prefer tirzepatide, which provides a direct way to study GLP-1/GIP interaction effects.

Researchers studying the emerging field of triple agonism and glucagon's role in metabolic regulation may prefer retatrutide, the most novel compound of the three.

For a more focused comparison of the first two compounds, see: Semaglutide vs Tirzepatide: What's the Difference?. For a deep dive on retatrutide, see: What Is Retatrutide?. View all lab results.

Selected Research References

• Wilding JPH, et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity." N Engl J Med. 2021. PMID: 33567185

• Jastreboff AM, et al. "Tirzepatide Once Weekly for the Treatment of Obesity." N Engl J Med. 2022. PMID: 35658024

• Jastreboff AM, et al. "Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial." N Engl J Med. 2023. PMID: 37351564

All products mentioned in this article are sold by Durham Peptides for research and laboratory use only. They are not intended for human or animal consumption, diagnosis, treatment, cure, or prevention of any disease.